Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENYSE:DNANASDAQ:IRONNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$41.96+1.9%$38.38$26.20▼$63.50$1.93B1.39553,167 shs637,466 shsDNAGinkgo Bioworks$8.53-0.5%$7.78$5.00▼$17.46$499.44M1.251.46 million shs987,316 shsIRONDisc Medicine$51.61+3.0%$47.22$30.82▼$68.73$1.79B0.73341,858 shs413,971 shsVERAVera Therapeutics$20.86-0.3%$22.49$18.53▼$51.61$1.33B1.13958,753 shs1.34 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%-5.67%+6.28%+2.74%+10.42%DNAGinkgo Bioworks0.00%-4.54%+22.07%+11.05%-59.64%IRONDisc Medicine0.00%-3.91%+8.95%-3.89%+16.82%VERAVera Therapeutics0.00%-8.27%+6.21%-23.17%-41.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.1765 of 5 stars3.51.00.00.01.54.20.0DNAGinkgo Bioworks0.8637 of 5 stars0.81.00.00.03.12.51.3IRONDisc Medicine2.3867 of 5 stars3.52.00.00.02.72.50.0VERAVera Therapeutics2.6018 of 5 stars4.61.00.00.01.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$94.60125.45% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-32.42% DownsideIRONDisc Medicine 3.09Buy$96.7087.37% UpsideVERAVera Therapeutics 3.10Buy$65.00211.60% UpsideCurrent Analyst Ratings BreakdownLatest DNA, APGE, VERA, and IRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.006/3/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/3/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.006/2/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $85.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ADNAGinkgo Bioworks$227.04M2.20N/AN/A$13.17 per share0.65IRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.00N/AN/AN/AN/A-40.59%-34.54%8/6/2025 (Estimated)Latest DNA, APGE, VERA, and IRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82DNAGinkgo BioworksN/A4.884.88IRONDisc Medicine0.0437.6537.65VERAVera Therapeutics0.1027.6827.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%DNAGinkgo Bioworks78.63%IRONDisc Medicine83.70%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%DNAGinkgo Bioworks9.72%IRONDisc Medicine4.24%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableVERAVera Therapeutics4063.77 million53.38 millionOptionableDNA, APGE, VERA, and IRON HeadlinesRecent News About These CompaniesAnalysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) PT at $65.00June 23 at 1:37 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesJune 20 at 2:22 AM | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19, 2025 | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest UpdateJune 18, 2025 | marketbeat.comBrokers Offer Predictions for VERA FY2026 EarningsJune 13, 2025 | americanbankingnews.comWedbush Equities Analysts Raise Earnings Estimates for VERAJune 13, 2025 | americanbankingnews.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)June 12, 2025 | marketbeat.comCantor Fitzgerald Comments on VERA FY2026 EarningsJune 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Increased by WedbushJune 11, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What HappenedJune 9, 2025 | marketbeat.comOtsuka, Vera stake their claims to IgAN treatmentJune 9, 2025 | pharmaphorum.comOtsuka's kidney disease therapy trial results heat up battle with rival VeraJune 6, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?June 6, 2025 | marketbeat.comBank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)June 6, 2025 | marketbeat.comWedbush Increases Earnings Estimates for Vera TherapeuticsJune 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)June 5, 2025 | marketbeat.comScotiabank Increases the Price Target for Vera Therapeutics by $10June 4, 2025 | msn.comVera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comVera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)June 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, APGE, VERA, and IRON Company DescriptionsApogee Therapeutics NASDAQ:APGE$41.96 +0.78 (+1.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$42.02 +0.05 (+0.13%) As of 06/20/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Ginkgo Bioworks NYSE:DNA$8.53 -0.05 (-0.55%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$8.37 -0.16 (-1.91%) As of 06/20/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Disc Medicine NASDAQ:IRON$51.61 +1.52 (+3.03%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$52.40 +0.79 (+1.52%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Vera Therapeutics NASDAQ:VERA$20.86 -0.06 (-0.29%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$21.04 +0.19 (+0.89%) As of 06/20/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
